Commentary on - "Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction"

to AEs was 3.6%. Zhao et al.4 performed a multicenter, randomized, double-blind, controlled trial to evaluate the efficacy and safety of once-daily dosing of udenafil in the treatment of ED. They found the incidence of AEs using udenafil 50 mg once-daily for ED patients was 10%. There are some differences in incidence rates of AEs among the studies.2–6 Thus, we believe that the AEs rate may be an important parameter to assess the drug safety. Meanwhile, we consider it is better to report the rate and classify of AEs contributed to objectively and fairly evaluate the safety between 50 mg once-daily and 200 mg on-demand dosing use of udenafil for the treatment of type 2 diabetic patients with ED, although most studies indicated AEs of udenafil for ED were safe.5,6